Mehrotra Parth

CEO Mehrotra sells ~121K shares across two days for ~$2.7M as stock trades well below 52-week highs; extends pattern of consistent selling.

Mehrotra Parth, Privia's CEO, disposed of approximately 121,000 shares over two consecutive trading days, reducing his direct stake from 555,443 to 434,357 shares. The sales occurred as the stock traded well below its 52-week high, and this filing represents his 39th open-market sale at PRVA over the past three years—underscoring a consistent and longstanding pattern of share reduction rather than accumulation. His prior five sales at this company showed mixed timing results: two were well-timed exits (stock fell afterward), but three saw the stock rise in the following periods, indicating he has not consistently exited at optimal moments. The company itself remains profitable with strong annual revenue growth, yet the CEO's unbroken chain of selling—without a single open-market purchase in the track record—suggests either consistent portfolio trimming or a view that current valuations do not warrant holding. Retail investors watching Privia should note this latest sale as part of a much larger pattern: the CEO has been a net seller at virtually every opportunity available to him.

CEO Mehrotra sells 26,509 shares at $22.11; stock down 18.2% from 52-week high and -3.6% in 30 days

CEO Parth Mehrotra sold 26,509 shares of Privia Health Group (PRVA) at $22.11 on 2026-03-16, reducing his holdings to 555,443 shares. The sale occurs as PRVA stock trades 18.2% below its 52-week high of $26.40 and has declined 3.6% over the past 30 days and 9.8% over 90 days. Mehrotra's cross-ticker track record shows 85.71% well-timed sales (average 90-day return of -8.4% after his prior sells), though his five most recent PRVA transactions (all between 2026-03-09 and 2026-03-13) have not yet reached measurable 90-day outcomes. The company trades at a steep P/E of 98.14 despite 22.3% annual revenue growth, with latest quarterly net income of only $6.9M on $580.4M in revenue.

CEO Mehrotra sells 53,992 shares (54.0K) for $1,172,077.78 at $21.71 avg; holds 581,952 post-transaction

Mehrotra executed 2 separate sales on consecutive days (2026-03-12 and 2026-03-13) totaling 53,992 shares (54.0K shares) for $1,172,077.78 ($1.2M), reducing his holdings by 8.5% from 635,944 shares to 581,952 shares. The sales occurred at $21.90 and $21.52, yielding a blended average price of $21.71, roughly in line with the current price of $21.96 but notably 16.8% below the 52-week high of $26.40. Mehrotra's cross-ticker open-market track record across 20 prior sells shows an 86.67% well-timed rate at the 90-day mark, but his prior trades at PRVA (5 trades, all recent) have not yet moved past the measurement window, making it impossible to assess timing accuracy at this specific ticker. The stock has declined 1.9% over 30 days and 7.8% over 90 days, and PRVA's valuation (P/E of 99.82) combined with the modest net income of $6.9M despite $580.4M in revenue suggests the company is in a high-growth, low-profitability phase.

CEO Mehrotra sells 63,439 shares ($1.5M) at $22.95–$23.37; now holds 343.8K (15.6% reduction)

Mehrotra, PRVA's CEO, executed 4 separate sales totaling 63,439 shares for $1,456,239.23 between March 6–9, 2026, reducing his stake by 15.6%. His cross-ticker sell track record shows a 90d well-timed rate of 88.89%, and at PRVA specifically, he has timed 4 of 5 prior sells well at the 90-day mark—including two consecutive May 2025 sales that preceded declines of 17.2% and 17.6% respectively. The current stock price of $22.47 sits 14.9% below the 52-week high, and despite +2.2% momentum over 30 days, the company trades at a P/E of 102.14 on $6.9M net income against $580.4M revenue, suggesting limited earnings cushion relative to valuation. The pattern of well-timed exits at this ticker and Mehrotra's demonstrated sell discipline across his portfolio warrant investor attention to whether this sale signals mounting conviction about near-term headwinds.

CEO Parth Mehrotra sold 29,682 shares for $734,275.95 across 2 dates; holds 407,234 post-transaction.

Mehrotra executed 2 separate sales totaling 29,682 shares for $734,275.95 on consecutive business days (May 12–13, 2025) at prices near the 52-week high ($24.99 and $24.52 versus the $25.69 peak). His cross-ticker track record shows 85.71% well-timed sales historically (average 90d return -6.3%), but at Privia specifically, timing has been mixed: 2 of 3 measurable prior trades fell post-sale (well-timed), while one rose 16.3%. The stock currently trades at $24.30 (near transaction prices, down 5.4% from the 52-week high). Against fundamentals showing modest revenue growth (+4.7% annual) and a stretched valuation (P/E of 186.92 on $4.2M net income), the timing and scale of these sales warrant attention to whether they reflect confidence constraints or liquidity needs in a company with tight margins relative to market cap.

Mehrotra sells 32,465 shares for $753.1K at PRVA; CEO retains 436.9K shares; pattern shows 4 of 5 prior PRVA sales were 90d well-timed.

Mehrotra, CEO of Privia Health Group, executed two separate sales totaling 32,465 shares for $753,067.20 on April 30 and May 1, 2025, reducing holdings by 6.9% to 436,916 shares. His same-ticker trade history at PRVA demonstrates a strong pattern of well-timed exits: 4 of 5 prior sales showed negative 90-day returns, indicating the stock declined after his sales. The current sale occurred as the stock trades at $23.32, within 9.2% of its 52-week high ($25.69), and within the recent transaction price range of $23.08–$23.33. The company shows modest fundamentals with annual revenue growth of 4.7% and a P/E ratio of 777.33 reflecting thin profitability ($3.5M net income on $437.9M revenue). The timing context—priced near 52-week highs and consistent with his prior pattern of sales ahead of subsequent declines—merits monitoring of post-sale price action to assess whether this transaction aligns with his demonstrated execution track record at this ticker.

CEO Mehrotra sold 135.1K PRVA shares at $18.50 for $2.5M; stock now -26.4% from 52-week high

Mehrotra sold 135,142 shares at $18.50 on 2024-09-10, reducing his stake by 27.0% to 365,106 shares post-transaction. His prior five sales at PRVA all posted negative 90-day returns (ranging from -7.4% to -22.1%), with a 100% rate of being well-timed at the 90-day mark. The current stock price of $18.84 is -26.4% from the 52-week high of $25.61, and at a P/E of 157.00 against net income of $3.5M on revenue of $422.3M, the valuation remains elevated despite recent weakness. The sale's sizing and his established pattern of well-timed exits at this ticker merit attention to whether this reflects a judgment about near-term value or execution of a pre-planned schedule.